Reata pharmaceuticals, inc. (RETA)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Sep'15Jun'15
Collaboration revenue

20,100

26,517

32,296

29,229

28,967

53,589

55,101

62,483

67,718

48,058

50,596

50,590

50,150

49,856

49,855

49,669

0

0

0

Expenses
Research and development

149,648

128,109

113,255

108,120

101,995

97,288

92,423

83,605

78,077

71,273

62,602

53,576

44,750

39,453

36,231

36,619

0

0

0

General and administrative

69,047

58,298

43,972

37,175

36,158

32,748

30,749

29,414

24,715

23,260

22,134

20,022

18,569

16,603

14,763

14,093

0

0

0

Depreciation

1,040

932

780

627

500

431

411

404

408

437

482

554

624

682

1,023

1,382

0

0

0

Total expenses

344,133

311,737

158,007

145,922

138,653

130,467

123,583

113,423

103,200

94,970

85,218

74,152

63,943

56,738

52,017

52,094

0

0

0

Investment income

-

-

6,568

6,351

-

-

2,135

1,239

955

-

453

317

272

214

122

68

0

0

0

Interest expense

-

-

9,603

9,574

-

-

4,269

2,393

1,958

-

0

0

0

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Other income (expense)

-

-

-

0

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Other income (expense), net

-8,156

-4,942

-3,028

-3,216

-4,068

-3,642

-3,141

-2,164

-1,006

-756

-507

-156

267

214

122

68

0

0

0

Loss before taxes on income

-332,189

-290,162

-128,739

-119,909

-113,754

-80,520

-71,623

-53,104

-36,488

-47,668

-35,129

-23,718

-13,526

-6,668

-2,040

-2,357

0

0

0

(Benefit from) provision for taxes on income

-22,234

8

69

37

0

-

0

0

-

-

0

0

-

-441

-582

-101

0

0

0

Net loss

-309,955

-290,170

-128,810

-119,951

-113,782

-80,546

-71,638

-53,111

-36,491

-47,671

-35,133

-23,722

-13,067

-6,227

-1,458

-2,256

0

0

0

Net loss per share—basic and diluted

-1.47

-6.10

-1.32

-1.14

-0.98

-

-1.07

-1.08

-

-

-0.50

-0.52

-

-0.20

-0.04

-0.05

-0.02

-

-

Weighted-average number of common shares used in net loss per share basic and diluted

33,222

31,647

30,110

30,069

29,830

-

28,704

26,178

-

-

24,845

22,365

-

22,389

22,324

18,562

15,990

-

-

Net (loss) income per share—basic

-

-

-

-

-

-

-

-

0.16

-

-

-

-0.32

-

-

-

-

0.04

-0.11

Net (loss) income per share—diluted

-

-

-

-

-

-

-

-

0.15

-

-

-

-0.32

-

-

-

-

0.04

-0.11

Weighted-average number of common shares used in net (loss) income per share basic

-

-

-

-

-

-

-

-

26,155

-

-

-

22,350

-

-

-

-

15,979

15,973

Weighted-average number of common shares used in net (loss) income per share diluted

-

-

-

-

-

-

-

-

26,633

-

-

-

22,350

-

-

-

-

16,149

15,973

License and milestone
Collaboration revenue

18,719

25,276

31,335

28,203

27,909

52,351

53,961

61,696

66,542

47,103

50,095

50,094

50,094

49,730

49,730

49,595

0

0

0

Other revenue
Collaboration revenue

1,381

1,241

961

1,026

1,058

1,238

1,140

787

1,176

955

501

496

56

126

0

0

0

-

-